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Abstract
Polymorphism or variation in DNA sequence can affect individual phenotypes such as 
color of skin or eyes, susceptible to diseases, and respond to drug, vaccine, chemical, and 
pathogen. It occurs more often than mutations (frequency ≥ 1%). The common polymor-
phism is single nucleotide polymorphism (SNP) which is a single base change in a DNA 
sequence that occurs most commonly in the human genome. SNPs have been used as 
molecular markers in a wide range of studies. Genome-wide association studies (GWAS) 
searches for SNPs that occur more frequently in person with a particular disease than in 
person without the disease and pinpoint genes or regions that may contribute to a risk of 
disease. This topic describes about polymorphisms, SNPs, GWAS, linkage disequilibrium 
(LD), minor allele frequency, haplotype, method for SNP genotyping, and application 
of SNPs and genome-wide association study in human diseases and drug development.
Keywords: drug development, genome-wide association studies, human diseases, 
polymorphisms, single nucleotide polymorphism, SNPs
1. Introduction
Phenotype of living organism is controlled by DNA. Variation in DNA sequence or polymor-
phism may make individual difference such as the differences in phenotype, risk of various 
diseases, and response to drugs, vaccine, chemical, and pathogen. Polymorphisms commonly 
occur in nature and related to biodiversity, genetic variation, and adaptation. It helps to main-
tain variety of forms in a population living in a varied environment [1]. It is preserved by 
frequency-dependent selection. The polymorphisms in this topic focus on human polymor-
phisms related to diseases and drug respond. Because the Human Genome Project had been 
completed, a large number of polymorphisms among the population have been found [2–4]. 
The most abundant type of the variations is single nucleotide polymorphisms (SNPs), with 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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more than 9 million reported in public databases [5–7]. In this chapter, the definition of sev-
eral terms such as polymorphism, minor allele frequency (MAF), allele frequency, haplotype, 
and linkage disequibrium (LD) is clarified. Moreover, SNPs, genome-wide association study 
(GWAS), methods to detect SNPs and application of SNPs in association with diseases and 
drug development are mainly discussed topics.
2. Polymorphisms
Genetic polymorphism, the definition by Cavalli-Sforza and Bodmer, is the occurrence in the 
same population of two or more alleles at one locus, each with appreciable frequency, where 
the minimum frequency is typically taken as 1% [8]. An allele is one of the variant forms of a 
gene at specific locus on a homologous chromosome. The different forms of the polymorphism 
(alleles) are observed more often in the general population than mutations. The most common 
polymorphism in the human genome is the single-nucleotide polymorphism (SNP) [9].
2.1. Single nucleotide polymorphism (SNP or snip)
SNPs are popular molecular genetic markers in disease genetics studies and pharmacoge-
nomic research. It is a single base change in a DNA sequence, with a normal alternative of 
two possible nucleotides at a given position. This variation occurs at a specific position in the 
genome and has allele frequency of 1% or greater [10]. Around 325 million, SNPs have been 
identified in the human genome, 15 million of which are present at frequencies of 1% or higher 
across different populations worldwide [11]. An example for SNP is shown in Figure 1. It 
demonstrates that at a specific position of human genome when compared between two indi-
viduals and two DNA sequences. The DNA sequence of a person 1 has C nucleotide which is 
similar to most of the other person (majority group), whereas the DNA sequence of a person 
2 has T at this position which is minority group of population. It is said that there is an SNP at 
this specific position between allele C or T.
The majority of SNPs have two alleles, which represent a substitution of one base for another. 
The SNP occurs at each allele of an individual may be different. If the SNP occurs more fre-
quently in the general population, it is called “major” allele. In contrast, if the frequency of the 
SNP exist is rare in the population, it is designated the “minor” allele. Since human have two 
copies of chromosome or diploid, therefore, an individual can have various genotypes such 
as homozygous of major or minor alleles, or heterozygous of major and minor allele [9]. Many 
SNPs are correlated with one another, so it is difficult to distinguish the SNP that affects the 
phenotype from the several SNPs associated with it [12].
SNPs are identified and characterized by sequencing the same genomic region in several pop-
ulations [13, 14]. The sample size of the population being resequenced is important. In general, 
larger sample sizes are needed to identify SNPs on the lower end of the minor allele frequency 
spectrum. The minor allele frequency (MAF) refers to the frequency at which the less com-
mon allele occurs in a given population. By using population genetics theory prediction for 
a SNP detection rate of 99%, a SNP with a minor allele frequency of 5% or greater needs 48 
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chromosomes, whereas a SNP with a minor allele frequency of 1% or greater requires 192 
chromosomes for the verification of genotype of SNP [15].
Currently, the genotyped in a large scale of SNPs can be performed by automated machines, 
which facilitate the genetic association study using DNA-based marker. Human Genome 
Project rank SNP discovery and characterization as high priorities [16, 17] and encourage 
public and private sections [4, 18, 19] to push an effort toward these objectives.
2.1.1. Effects of SNPs location
The location of SNPs may affect gene products and others. The SNPs within a gene may alter 
protein structures. The SNPs in the regulatory region outside a gene may affect when and 
how the gene is turned on, which affects the quantity of the protein produced. They also 
affect gene splicing, transcription factor binding, or the sequence of non-coding RNA. The 
SNPs that are not within the proximity of a gene may be used as genetic markers for locating 
disease-causing genes (Figure 2).
2.1.2. Types of SNPs
As described earlier, the SNPs may fall within coding sequences of gene, or non-coding regions 
of gene, or in the intergenic regions (regions between genes). The SNPs in the coding region of 
gene are divided into two types: synonymous and nonsynonymous SNPs. The synonymous 
SNPs do not change the amino acid sequence of protein or not affect the protein function. The 
nonsynonymous SNPs are divided into two types: missense and nonsense. A missense SNP, 
single nucleotide change results in a codon that codes for a different amino acid, resulting in 
protein nonfunction. For nonsense, a point mutation in a sequence of DNA that changes to a 
stop codon results in a nonfunctional protein product. SNPs that are in non-coding regions 
Figure 1. Single nucleotide polymorphism (SNP). (http://en.wikipedia.org/wiki/Single-nucleotide_polymorphism).
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of gene, or in the intergenic regions may affect gene splicing (SNPs at intron region), tran-
scription factor binding (SNPs at 5′ untranslated region), messenger RNA degradation, or the 
sequence of non-coding RNA. The type of SNPs located upstream or downstream from the 
gene that affect gene expression is referred to an expression SNP (eSNP).
3. Association study
By comparing the patterns with patterns obtained by analyzing the DNA from a group of 
individuals affected and unaffected by the disease is called as an ‘association study’. This 
study demonstrates the linking between the polymorphism and diseases or drug respond.
3.1. Minor allele frequency
Minor allele frequency (MAF) refers to the frequency at which the less common allele occurs 
in a given population. MAF is widely employed in GWAS for complex traits [20]. SNPs with a 
minor allele frequency of 5% or greater were targeted by the HapMap project.
3.2. Allele frequency and genotype frequency
Allele frequency is the relative frequency of an allele at a particular locus in a population.
Genotype frequency in a population is the sum of the individuals with the same genotype 
divided by the total number of individual in that population. In addition, the genotype fre-
quency, in population genetics, means the proportion or frequency of genotypes in a popula-
tion (0 < f < 1). The genotype frequency may also be used in the genomic profiling to predict 
someone is having a disease [21] or even a birth [22] defect. It can also be used to determine 
ethnic diversity.
3.3. Haplotypes
Haplotypes are a combination of alleles at different markers along the same chromosome 
that is inherited as a unit. Each haplotype is a combination of major and minor alleles along 
Figure 2. SNP location.
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the chromosomes, and each individual is represented twice to account for the maternal and 
paternal contributions [9]. The fundamental difference between haplotypes and individual 
genotypes at SNPs is that the alleles are assigned to a chromosome.
Haplotypes inform about the exchange of DNA during meiosis or recombination, which is 
useful for locating the mutation that are associate with diseases by using linkage method. It 
has an effect on linkage disequilibrium.
3.4. Linkage disequilibrium (LD)
In population genetics, linkage disequilibrium (LD) is the non-random association of alleles 
at different loci in a given population that may or may not be on the same chromosome. Loci 
are said to be in linkage disequilibrium when the frequency of association of their different 
alleles is higher or lower than what would be expected if the loci were independent and asso-
ciated randomly [23]. LD can detect differences between the SNP patterns of the two groups 
and reveal which pattern is most likely associated with the disease-causing gene or response 
to certain drugs.
LD is an important concept in genetic studies that aims to identify and localize genes related 
to disease susceptibility. LD is commonly used to indicate that two genes are physically 
linked. It is defined as the difference between the observed frequency of a particular combi-
nation of alleles at two loci and the frequency expected for random formation of haplotypes 
from alleles. The frequency of a particular allele at a given locus will be independent of alleles 
at other linked loci. LD plays a crucial role in the current methods for mapping complex dis-
ease or trait-associated genes or plays a key role in health and disease. The level of linkage 
disequilibrium is influenced by a number of factors such as genetic linkage, selection, the rate 
of recombination, the rate of mutation, genetic drift, non-random mating, and population 
structure.
3.5. Genome-wide association studies (GWAS)
GWAS identify the common disease-causing variants by using high throughput genotyp-
ing equipment to examine hundreds of thousands of common SNPs and compare these 
common genetic variants in large numbers of affected cases (patient) to those in unaffected 
controls (non-patient) to determine whether have an association with disease (Figure 3) 
[24, 25].
In most chromosome regions, there is strong association among SNP, therefore, only a few 
SNPs in each region are selected to be sequenced to predict the alleles of the remaining 
SNPs in that region. An accurate mapping of LD pattern among SNPs which differ across 
ancestral groups is required for selecting the best tag SNPs. The precise LD maps are needed 
to help genetic association studies and stimulated the developing of human haplotype map 
[26, 27]. GWAS pinpoint genes that may contribute to a risk of developing disease. The data 
derived from GWAS inform about disease etiology, therapeutic targets, and gene function 
[28].
Polymorphisms
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4. Method for detection of SNPs
SNP genotyping strategies typically involve allele-discrimination and allele-detection. The 
other methods based on physical properties of DNA [29].
4.1. Allele-discrimination
4.1.1. Primer extension
These approaches involve allele-specific incorporation of nucleotides in primer extension 
reaction with a DNA template, utilizing enzyme specificity to accomplish allelic discrimi-
nation. In the reaction of a common primer extension (CPE) protocol, a designed primer is 
annealing with its 3′ end near a SNP site and nucleotides are added by polymerase enzyme 
[30]. The extended nucleotide is examined by either mass or fluorescence to verify SNP geno-
type. Because of the simplicity in primer and assay design, it can detect multiple SNPs at the 
same time, therefore, several SNP genotyping use CPE [29]. CPE-based methods that use 
MALDI-TOF MS (matrix assisted laser desorption/ionization time-of-flight mass spectrom-
etry) for the discrimination of alleles include PinPoint assay [31, 32], MassEXTEND™ [33, 34], 
SPC-single base extension (SBE) [35], and GOOD assay [36]. In the reaction of these methods, 
SNP-specific primers are simultaneously extended with numerous nucleotides using PCR 
products as a template yielding extended products of dissimilar masses. The genotypes of 
SNPs of the products are examined by mass analysis (Figure 4a). The PinPoint assay performs 
the simplest technique by using dideoxynucleotides (ddNTPs) for single base extension (SBE) 
Figure 3. Genome-wide association studies (GWAS). (http://mmg-233-2014-genetics-genomics.wikia.com/wiki/File:GWAS.
jpg).
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of primer [31, 32]. The CPE approaches that use fluorescence-based detection involve SBE 
of primer with fluorescently labeled ddNTPs (Figure 4b). Specific primer extension (SPE) 
methods use two primers that have the same nucleotide sequences except specific allele/base 
at their 3′ end. The primers can extend if the nucleotide at their 3′ end of the primers perfectly 
binds with the SNP of complementary template, then allelic discrimination can be examined 
by mass different using gel electrophoresis (Figure 4c).
MassEXTEND™ procedure uses a mixture of dNTPs and ddNTPs for primer extension and 
discriminate the allele by mass detection. It provides medium-to-high-throughput genotyping 
Figure 4. Primer extension approaches for SNP genotyping. (a) Mass spectrometry-based detection. This method uses 
a primer that anneals one base upstream of the SNP site followed by its extension with ddNTPs. Extension products 
are detected by mass spectrometry, and the difference between mass of extension product and primer identifies 
incorporated nucleotide(s) and therefore the SNP genotype. (b) Fluorescence detection using capillary electrophoresis. 
This technique uses a primer that anneals one base upstream of the SNP site after that its extension with ddNTPs that are 
labeled with different fluorescent tags. Products are detected by fluorescence after capillary electrophoresis and the color 
of dye indicates incorporated base(s). (c) Allele-specific primers with detection of PCR products. This method uses two 
allele-specific primers that anneal with their 3′ ends at the SNP site and a common reverse primer (not shown) for PCR 
reaction. The amplification occurs when the forward primer perfectly matches to the SNP at its 3′ end and the genotype 
can be determined by gel electrophoresis of PCR product [29].
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that can be used to genotype a group of SNPs in candidate genes, SNPs for GWAS and SNPs 
in a large sample set [33, 34].
4.1.2. Hybridization
Hybridization methods use differences in thermal stability of double-stranded DNA to 
separate between perfectly matched and mismatched target-probe pairs for succeed-
ing allelic discrimination. Hybridization methods have been applied on high-through-
put platforms using microarrays (Figure 5a). In the GeneChip® array technology 
(Affymetrix, CA) protocol, probe array is synthesized in an ordered fashion on a solid 
surface using 25-bases oligonucleotides with specific allele by photolithography [37]. 
Figure 5. Hybridization-based approaches for SNP genotyping. (a) Target hybridization to a probe array. This method 
uses allele-specific probes attached to a solid surface for hybridization with tagged-targets containing SNPs. The surface 
is washed to remove mismatched targets, then the genotype of the perfectly matched target-probe pairs is detected by 
fluorescence. (b) TaqMan® assay. The assay uses two allele-specific probes with different dyes, reporter (R) and quencher 
(Q), at either end with a mismatch at the SNP site. The perfectly matched probe is cleaved during PCR amplification of 
the SNP-containing region, release its reporter, and the SNP genotype indicates by fluorescence analysis [29].
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The DNA fragment containing SNPs are amplified from genomic DNA. The PCR prod-
ucts are cleaved, tagged, and hybridized to the probe array under stringent conditions, 
then wash, and label with fluorescent. The genotypes of SNPs are examined from the 
fluorescence signal based on probe-target hybridization. Numerous probes that differ 
at a single base are used to confirm each SNP to increase genotyping accuracy. In this 
method, a single array contains millions of probes and be used for parallel genotyp-
ing of 104 to approximately 105 SNPs [38]. The TaqMan® genotyping assay (Applied 
Biosystems, CA) combines the procedure of hybridization and 5′ nuclease activity of 
polymerase coupled with fluorescence detection (Figure 5b). It employs four oligonu-
cleotides containing two allele-specific oligonucleotide probes that have a single base 
mismatch and a pair of PCR primers neighboring the SNP covering region [29, 39].
4.1.3. Ligation
Ligation method discriminates the allele by using specificity of ligase enzymes. When two 
oligonucleotides (allele-specific probes and ligation probes) hybridize to single-stranded tem-
plate DNA with perfect complementarity, they are nearby to each other, then ligase enzymes 
join them together to form a single oligonucleotide. Normally, three oligonucleotide probes 
are used in ligation assays, two probes are allele specific that bind to the template at the SNP 
site and ligation probe [40]. Combinatorial fluorescence energy transfer (CFET) tags have been 
used with ligation for SNP genotyping [41]. CFET tags are composed of fluorescent dyes that 
can transfer energy when they are in close proximity. For SNP genotyping, two probes of allele 
specific are labeled with CFET tags and common probe is labeled with biotin (Figure 6a). After 
the ligation reaction, product is separated using the biotin-streptavidin interaction. Genotyping 
is carried out by using capillary array gel electrophoresis based on tag fluorescence. In Padlock 
technology, a linear oligonucleotide probe is used with its ends designed to mimic the allele-
specific probe and common probe for ligation at the SNP site (Figure 6b).
4.1.4. Enzymatic cleavage
The method is based on the capacity of enzymes to cleave DNA by recognition of specific 
sequences and structures. Difference between alleles can be discriminated when SNPs are 
located in an enzyme recognition site and affect the enzyme activity.
The ability of restriction enzymes has been used for detection of genetic variation by the 
method of restriction fragment length polymorphism (RFLP) [42]. These enzymes recognize 
specific sequences in double-stranded DNA and cleave both strands at a specific site in the 
sequence or near it to generate smaller DNA fragments (Figure 7a). For SNP genotyping, the 
PCR product containing the SNP is incubated with appropriate restriction enzyme and sepa-
rated by gel electrophoresis. The SNP genotype is simply determined from sizes of the digested 
products. This method does not need any probes but it has limited amount and a number 
of SNPs.
The Invader® assay (Third Wave™ Technologies, WI) utilizes structure-specific cleavage by a 
flap endonuclease enzyme (Figure 7b). It uses three probes for genotyping a SNP, two allele-
specific probes and a third common probe (invader) [43].
Polymorphisms
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4.2. Allele detection methods
4.2.1. Mass-based detection
For mass analysis of oligonucleotides, MALDI-TOF MS is a widely used method. It involves 
the use of a small organic molecule termed matrix that absorbs energy from a laser source of 
certain wavelength for ionization. When analytes are mixed and cocrystallized with matrix, 
they are ionized in the form of intact molecules owing to transfer of energy from the matrix 
molecules [44, 45]. Figure 8 demonstrates a multiplex SNP genotyping by primer extension 
and MALDI-TOF MS detection.
Figure 6. Ligation-based SNP genotyping approaches using ligase enzymes. (a) Detection using CFET labels. This protocol 
uses two allele-specific probes that have different CFET labels and a biotin-tagged common probe that hybridizes adjacent to 
them. Allele-specific probe and common probe bind to the template containing SNP. If the sequences are perfectly matches at 
SNP site, the two probes are ligated. The ligated product is proved by isolation using the biotin tag on the common probe and 
the fluorescence signal from the CFET label to indicate SNP genotype. (b) Ligation of padlock probe. This method uses two 
allele-specific probes that hybridize to target DNA with their ends aligned end-to-end at the SNP site. One end of the probe 
is allele-specific that is ligated to the other end only when there is a perfect match at the SNP site, leading to circularization of 
the probe. After rolling circle amplification using a specific prime, the product is analyzed by gel electrophoresis [29].
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4.2.2. Fluorescence signal-based detection
Monitoring fluorescence signal is widely used in genotyping technologies because its operation 
is simple and detection is fast with high sensitivity. Fluorescence detection is used for direct 
sequencing (DS) using capillary array electrophoresis. Fluorescence polarization (FP)-based 
detection uses the change in polarization of plane polarized light by a fluorescent dye molecule 
owing to change in its molecular weight under conditions of constant temperature and solvent 
viscosity [46]. FP has been coupled with other SNP genotyping techniques including TaqMan® 
and Invader® [47]. TaqMan® assay is a single-step assay that uses fluorescence-based detection. 
Figure 7. Enzymatic cleavage for SNP genotyping. (a) Digested with specific restriction enzyme. This method uses a 
restriction enzyme that cleaves only one of the alleles. The digested products are run on agarose gel electrophoresis, 
and the SNP genotype is determined based on the size and number of DNA fragments. (b) Invader® assay. This 
assay uses two allele-specific probes with different dyes, reporter (R) and quencher (Q), at either end or one common 
invader probe. The allele-specific probe and invader probe hybridize with target DNA to form a three-dimensional 
structure at the SNP site which recognized by cleavase enzyme. The allele-specific probe that complementary to 
the SNP is cleaved by the enzyme and releases its reporter dye in which SNP genotype can be discriminated by 
fluorescence analysis [29].
Polymorphisms
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It is well suited for low-to-medium throughput genotyping applications but is currently limited 
to genotyping of one SNP per assay.
4.2.3. Chemiluminescence
Chemiluminescence has several advantages as a detection technique, such as high signal-
to-noise ratio, rapid detection, and feasibility for automation. Pyrosequencing™ (Biotage, 
Sweden) employs chemiluminescence-based detection for SNP genotyping using a cascade 
Figure 8. Multiplex SNP genotyping by primer extension and MALDI-TOF MS [29]. First, genomic DNA is amplified 
in multiplex PCR reaction, and the PCR products are used for a primer extension reaction with a collection of primers 
specific to each SNP site. The mass of the primer indicates SNP, and the mass difference between primer and its extension 
product(s) tells identity of incorporated nucleotide(s) and the genotype. (a) MassEXTENDtm method in which primers 
are prolonged with a specific mixture of dNTPs and ddNTPs by one or more bases, specific to each allele. (b) Modified 
PinPoint method using mass-tagged ddNTPs for primer extension. This increases mass difference between extension 
products of alleles of a SNP, when compared with regular ddNTPs, increasing the accuracy of genotyping. (c) SPC-SBE 
method relating the production of primer extension products with biotinylated ddNTPs for isolation on a solid surface. 
This excludes excess primers from the mass spectrum, permitting the analysis of more products at the same time [29].
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of enzyme reactions [48]. Pyrosequencing™ is an approach that combines sequencing-by-
synthesis with chemiluminescence detection. In SNP genotype, it provides sequence informa-
tion on the region surrounding the SNP site.
4.3. The other methods
4.3.1. Single-strand conformation polymorphism (SSCP)
SSCP discriminates the allele by using secondary structure of single-stranded DNA. The single-
stranded DNA molecules which differ at a single base run on a nondenaturing gel electrophoresis 
display different mobility based on their native conformations (Figure 9) [49].
Figure 9. Single-strand conformation polymorphism (SSCP) (https://media.nature.com/m685/nature-assets/nprot/journal/
v1/n6/images/nprot.2006.485-F1.jpg).
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Figure 10. High resolution melting (HRM) analysis (https://www.dna.utah.edu/Image/Hi_Res%20Melting_Normalized.
JPG).
4.3.2. High resolution melting analysis (HRM)
This method, the fragment cover SNP is amplified by real-time PCR and followed by 
HRM. The HRM is a technique for the detection mutations and SNPs, which based on analy-
sis of melting curve when double-strand DNA (dsDNA) separate into single-strand DNA 
(ssDNA) during increased temperature from around 50°C up to around 95°C. At some point 
during this process, the melting temperature of the amplicon is reached and the two strands 
of DNA separate. This can visualize the melting behavior of the product through a fluorescent 
dye [50]. The fluorescent dye binds to double-strand DNA during the amplification resulting 
in an increase of fluorescence (Figure 10). This method is simple, cost-effective, fast and able 
to accurately genotype many samples rapidly. It also reduces the need to design multiple 
pairs of primers or purchase expensive probes.
4.3.3. Denaturing high performance liquid chromatography (DHPLC)
It is a method for screening DNA samples for SNPs and inherited mutations. The analysis 
begins with a PCR amplification, followed by a step of denaturation-renaturation to create 
hetero-and homoduplexes from the two populations in the PCR. The heteroduplexes with mis-
match pairing and homoduplex can be detected on reversed-phase chromatography of dena-
turing high performance liquid chromatography (DHPLC). The heteroduplexes thermally that 
less stable than their corresponding homoduplexes will be resolved by chromatography when 
subjected to a sufficiently high temperature. This mismatch will decrease the interaction with 
the column and a reduced retention time compared to the homoduplexes (Figure 11).
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5. Application of SNPs
5.1. SNPs as biological markers of human diseases
Most SNPs are not responsible for a disease state. They serve as biological markers for pin-
pointing a disease on the human genome map. SNPs occur on average once every 200 base 
pairs [18, 51–53] in the human genome. Common SNPs (a minor allele frequency range from 
5% to >20%) can explain a proportion of common human disease. Most SNPs do not occur in 
the coding region of genes or even in genes [4]. Nonsynonymous SNPs that suspect in causing 
a human disease do not account for all SNPs that can cause disease or susceptibility to disease. 
Other functional SNPs associated with human disease or susceptibility to disease includes 
SNPs located in promoters [54, 55], introns [56], splice sites [57], and intragenic region [56, 
58]. Even synonymous SNPs have been involved in functional consequences via unknown 
mechanism [59].
5.2. SNPs and drug development
Variants of genes encoding drug metabolizing enzymes or drug targets have been studied 
in association with personal drug responses. SNPs are popular molecular markers in such 
pharmacogenomics studies. Using SNPs to study the genetics of drug response will help in 
the creation of personalized medicine or the most appropriate drug for an individual and 
could be determined in advance of treatment by analyzing a patient’s SNP profile. SNPs may 
Figure 11. Denaturing high performance liquid chromatography (DHPLC) (http://www.tankonyvtar.hu/en/tartalom/
tamop425/0011_1A_Molelkularis_diagnoszitka_en_book/images/image047.png).
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be associated with the absorbance and clearance of therapeutic agents. The association of dif-
ferent SNPs with a wide range of human diseases such as cancer, infectious diseases autoim-
mune, neuropsychiatric and others can be used as targets for drug therapy [60].
6. Studies of SNPs in association with human diseases
6.1. Cancer
Cancer is a disease that involves abnormal cell growth. There are several kinds of cancers. 
Gemignani et al. studied polymorphisms in dopamine receptor gene, DRD2, in association 
with colorectal cancer risk utilizing the APEX system which is primer extension assays that use 
fluorescence and mass detection [61]. They genotyped seven SNPs of DRD2 in 370 case and 327 
control samples and found three of the seven SNPs to be highly associated with colorectal can-
cer, related to reduced levels of D2 dopamine receptor. Hartikainen et al. investigated genes 
associated with breast cancer in an eastern Finnish population [62]. Ten SNPs were genotyped 
in the 22q12-q13 region from DNA of 497 patients and 458 control subjects using the TaqMan® 
assay. The SNP, rs733655, in matriptase-2 gene (TMPRSS6) was found to have a strong associa-
tion with risk of breast cancer. Ribas et al. genotyped 899 SNPs in 175 candidate cancer genes 
from Spanish population using BeadARRAY™ and SNPlex™ methods to evaluate applicabil-
ity of HapMap data (for subjects of European ancestry) to cancer research. They found that 
allele frequencies and haplotype distributions obtained in the study were consistent with the 
HapMap data [63]. Shatalova et al. examined SNPs in sulfotransferase 1A1 (SULT1A1) and 
UDP-glucorono-syltransferase 1A1 (UGT1A1) genes in 119 patients with breast cancer and 121 
controls using Pyrosequencing™ [64]. They found only UGT1A1 gene to be associated with 
risk of breast cancer. Copson et al. genotyped a T/G SNP (SNP309) in the MDM2 gene in 116 
patients with pathogenic mutations in BRCA1 gene and 102 healthy controls [65]. Results sug-
gested that the MDM2 SNP309 locus does not have a significant association with accelerated 
cancer development in carriers of known pathogenic mutations of BRCA1.
6.2. Schizophrenia
Schizophrenia is a severe psychiatric disorder characterized by hallucinations, delusions, cog-
nitive deficits, and apathy, with a lifetime prevalence of ∼1%. Epidemiologic studies on twins 
indicate that schizophrenia has a complex genetic background with heritability estimated at 
73–90%.
Arinami et al. genotyped 5861 SNPs of 602 individuals from 236 Japanese families using the 
BeadARRAY™ Linkage Panel (IV) for the genome-wide linkage analysis [66]. They found a 
strong association of schizophrenia to the region 1p21-p13 and implied that schizophrenia might 
have common susceptibility loci across populations with different ethnicity-specific effects.
Panichareon B et al. used GWAS-discovered SNPs of Europeans ancestry in OPCML gene 
and investigated SNPs in Thai schizophrenia patient by using polymerase chain reaction 
(PCR) and high-resolution melting (HRM) analysis. The results of this study found a strong 
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association between an intronic SNP (rs1784519) and the risk of schizophrenia in a Thai pop-
ulation [p = 0.00036, odds ratio for the minor A allele: 2.11(1.57–2.84)] [67].
6.3. Dyslipidemia
Dyslipidemia is an abnormal of lipid and/or lipoproteins in the blood. It is a major risk fac-
tor of coronary heart disease and atherosclerosis. A genome-wide association study (GWAS) 
examined the concentrations of HDL-C and triglyceride in European ethic and identified the 
SNP at 15 loci which associated with HDL-C levels (such as, APOA1/C3/A4/A5 gene cluster) 
and SNPs at 12 loci associated with triglycerides (such as APOB, APOE gene) [68]. Thongket 
et al. examined SNP in apolipoprotein E receptor 2 gene using real-time PCR and HRM analy-
sis and found that the rs2297660 showed strong association with risk of dyslipidemia in Thai 
population [69].
6.4. Diabetes mellitus
Diabetes mellitus (DM) is a group of metabolic disorders. Untreated diabetes patient can cause 
many complications. Acute complications can include diabetic ketoacidosis, hyperosmolar 
hyperglycemic state, or death [70]. SNPs in the gene encoding aldose reductase (AKR1B1) were 
studied for their association with diabetic nephropathy by Wolford et al. They genotyped eight 
SNPs of AKR1B1 gene in two different case control sets by Pyrosequencing™ method and found 
that common AKR1B1 SNPs were unlikely to be major determinants of diabetic nephropathy 
[71]. Altshuler et al. genotyped SNPs from 3000 individuals to investigated the association of 
two polymorphisms, a missense variant in PPARG (Pro12Ala) and a silent C/T polymorphism 
in exon 22 of ABCC8, with type 2 diabetes using FRET and FP methods. It was found that only 
Pro12Ala showed a significant association with decreased risk of type 2 diabetes [72].
7. Conclusion
Polymorphism is a variation in DNA sequence that may affect individual phenotypes. It 
occurs more often in the general population than mutations (frequency ≥ 1%). The majority 
of variation is single nucleotide polymorphism (SNP) which is a single base change in a DNA 
sequence that occurs at a specific position in the genome. SNP may locate within coding, or 
non-coding, or intergenic regions of genes. Most of SNPs have two alleles, for an individual 
SNP, one is major allele and the other is the minor allele based on their observed frequency 
in the general population. Genome-wide association studies (GWAS) search for SNPs that 
occur more frequently in person with a particular disease than in person without the disease 
and pinpoint genes that may contribute to risk of disease. Linkage disequilibrium (LD) is 
commonly used to indicate that two or more genes are physically linked. It plays an impor-
tant role in health and disease. Most SNPs are not responsible for a disease state but serve 
as biological markers for various complex diseases such as cancer, diabetes, dyslipidemia, 
schizophrenia, and so on. There are several methods for analyzing SNPs such as MALDI-TOF 
MS, GeneChip® array, pyrosequencing, DHPLC, HRM, RFLP, and so on.
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